The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
The advancement of new therapies, including targeted therapies and immunotherapies, has improved the survival of non-small-cell lung cancer (NSCLC) patients in the last decade. Some NSCLC patients still do not benefit from therapies or encounter progressive disease during the course of treatment bec...
Main Authors: | Ping-Chih Hsu, Cheng-Ta Yang, David M. Jablons, Liang You |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/6/1361 |
Similar Items
-
Dasatinib targets c-Src kinase in cardiotoxicity
by: Manar Elmadani, et al.
Published: (2023-01-01) -
MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer
by: Na-Hyun Lee, et al.
Published: (2021-03-01) -
YES, a novel therapeutic target in hepatocellular carcinoma
by: Marjorie Lapouge, et al.
Published: (2022-12-01) -
CCDC25 suppresses clear cell renal cell carcinoma progression by LATS1/YAP-mediated regulation of the hippo pathway
by: Hongpei Tan, et al.
Published: (2024-04-01) -
Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis
by: Taha Azad, et al.
Published: (2020-07-01)